Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AK119 in advanced solid tumors
NCT05173792Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Dec 2021
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in solid tumor (advanced stage), sponsored by Akeso, Inc. Primary endpoints: Adverse Events and Dose Limiting Toxicity at 4 weeks. Started Dec 2021; status: completed.
02
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05173792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05173792.